Carlsquare advised Mérieux Equity Partners (“MxEP”), a healthcare-focused investment firm with a Venture Capital and Buyout platform, on the acquisition financing for curea in March 2025.
Established in 2009, MxEP has completed 50+ healthcare & nutrition deals and has more than EUR 1.5bn AuM. Leveraging deep expertise and a vast network, MxEP supports companies with ambitious growth plans and transformative healthcare innovations. This carve-out of the leading DACH-region wound care provider aligns perfectly with MxEP ‘s focus on innovative healthcare.
curea medical (“curea”), a German manufacturer based in Heilbad Heiligenstadt, specializes in innovative wound care solutions, particularly superabsorbent dressings with proprietary SuperCore® technology for superior fluid management. Serving homecare companies, distributors and retailers, pharmaceutical wholesalers and hospitals, curea is a key player in advanced wound care through continuous innovation and high-quality manufacturing.
This transaction is supported by NORD/LB, a leading DACH-region lender with a proven track record in providing bespoke mid-market LBO financing solutions.
To address the company’s working capital needs, the newly established financing facility includes, next to the acquisition term loans, a revolving credit facility.
“We deeply appreciate the Carlsquare Debt Advisory Team’s efficient and successful guidance throughout this acquisition financing process. curea stands out for its cutting-edge solutions in advanced wound care, and we see significant growth potential across Europe. Our ambition is to build a leading European player in superabsorbent dressings, leveraging curea’s technological expertise and state-of-the-art manufacturing capabilities in Germany.” – Jaana Grüter and Theodor Wuppermann, Partners, Mérieux Equity Partners
Carlsquare acted as the exclusive debt advisor to Mérieux Equity Partners.
